Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.46 |
| ▸ | GNRHR | P30968 | 1/20 | 0.42 |
| ▸ | STING1 | Q86WV6 | 6/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 3/20 | 0.38 |
| ▸ | ITK | Q08881 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7879921 | 0.92 | GNRHR (0.43) | GRM2GNRHRSTING1HDAC1HDAC8 | |
| SCHEMBL6245220 | 0.90 | GRM2 (0.47) | GRM2GNRHRSTING1HDAC1HDAC8 | |
| SCHEMBL31069435 | 0.87 | GRM2 (0.47) | GRM2GNRHRHDAC1HDAC8CYP3A4 | |
| SCHEMBL3746499 | 0.86 | HDAC1 (0.41) | HDAC1HDAC8ITK | |
| SCHEMBL6242216 | 0.86 | GNRHR (0.43) | GRM2GNRHRSTING1HDAC1HDAC8 | |
| SCHEMBL6218923 | 0.85 | CNR2 (0.49) | GRM2HDAC1HDAC8 | |
| SCHEMBL6493464 | 0.84 | GRM2 (0.42) | GRM2GNRHRSTING1HDAC1HDAC8 | |
| SCHEMBL31069459 | 0.83 | KDM4E (0.41) | GRM2STING1CYP3A4CYP2C19L3MBTL1 | |
| SCHEMBL3737024 | 0.83 | GNRHR (0.48) | GNRHRSTING1HDAC1HDAC8CYP3A4 | |
| SCHEMBL31069437 | 0.80 | CYP3A4 (0.44) | GRM2GNRHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204375-B1 | SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) | REVIRAL LTD (GB) | 2019-02-13 | — | — | EP | disclosed |
| US-10106539-B2 | Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV) | ReViral Limited (GB) | 2018-10-23 | — | — | US | disclosed |
| US-20170305908-A1 | SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) | ReViral Limited (GB) | 2017-10-26 | — | — | US | disclosed |
| EP-3204375-A1 | SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) | Reviral Limited (GB) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016055780-A1 | SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) | RE:VIRAL LTD (GB) | 2016-04-14 | — | — | WO | disclosed |
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | ASTRAZENECA UK LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| WO-2010103306-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS ANTIVARAL AGENTS | ASTRAZENECA UK LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305908-A1 | SPIRO-INDOLINES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION (RSV) | NR3C2, SAV1, ACE2 | GRM2 1917/4885GNRHR 4740/4885STING1 2967/4885 |
| US-20100278835-A1 | NOVEL COMPOUNDS 660 | RB1, RPP30, SARS1 | GRM2 2069/4885GNRHR 2966/4885STING1 1848/4885 |
| US-10106539-B2 | Spiro-indolines for the treatment and prophylaxis of respiratory syncytial virus infection (RSV) | SPTBN1, NR3C2, SPNS2 | GRM2 1741/4885GNRHR 4777/4885STING1 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.